Earnings Feed
Start Free
BridgeBio Pharma, Inc.·4

Nov 14, 4:50 PM ET

Valantine Hannah 4

4 · BridgeBio Pharma, Inc. · Filed Nov 14, 2025

Insider Transaction Report

Form 4
Period: 2025-11-12
BridgeBio Pharma, Inc.BBIO
Valantine Hannah
Director
Transactions
  • Exercise/Conversion

    Common Stock

    2025-11-12$48.45/sh+25,484$1,234,700→ 32,949 total
  • Sale

    Common Stock

    2025-11-12$66.07/sh−25,484$1,683,728→ 7,465 total
  • Exercise/Conversion

    Stock Option (Right to Buy)

    2025-11-12−25,484→ 25,484 total
    Exercise: $48.45Exp: 2031-10-24→ Common Stock (25,484 underlying)
Holdings

  • Common Stock

    (indirect: By Spouse)
    398
Footnotes (1)
  • [F1]The stock option vested and became exercisable in three annual installments after October 25, 2021.

Documents

4 files
  • 4
    wk-form4_1763157038.xmlPrimary

    FORM 4

  • EX-24
    hannahvalentine.htm

    EX-24

  • GRAPHIC
    hannahvalentine001.jpg
  • GRAPHIC
    hannahvalentine002.jpg